Sensory neuron–derived NaV1.7 contributes to dorsal horn neuron excitability by Alles, Sascha R. A. et al.
Alles et al., Sci. Adv. 2020; 6 : eaax4568     19 February 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
1 of 7
N E U R O S C I E N C E
Sensory neuron–derived NaV1.7 contributes to dorsal 
horn neuron excitability
Sascha R. A. Alles1*, Filipe Nascimento2*, Rafael Luján3*, Ana P. Luiz1, Queensta Millet1, 
M. Ali Bangash1, Sonia Santana-Varela1, Xuelong Zhou1,4, James J. Cox1, Andrei L. Okorokov1, 
Marco Beato2†, Jing Zhao1*†, John N. Wood1†
Expression of the voltage-gated sodium channel NaV1.7 in sensory neurons is required for pain sensation. We 
examined the role of NaV1.7 in the dorsal horn of the spinal cord using an epitope-tagged NaV1.7 knock-in mouse. 
Immuno–electron microscopy showed the presence of NaV1.7 in dendrites of superficial dorsal horn neurons, de-
spite the absence of mRNA. Rhizotomy of L5 afferent nerves lowered the levels of NaV1.7 in the dorsal horn. Pe-
ripheral nervous system–specific NaV1.7 null mutant mice showed central deficits, with lamina II dorsal horn tonic 
firing neurons more than halved and single spiking neurons more than doubled. NaV1.7 blocker PF05089771 di-
minished excitability in dorsal horn neurons but had no effect on NaV1.7 null mutant mice. These data demon-
strate an unsuspected functional role of primary afferent neuron-generated NaV1.7 in dorsal horn neurons and an 
expression pattern that would not be predicted by transcriptomic analysis.
INTRODUCTION
The problem of pain continues to grow, and new analgesic approaches 
are urgently required (1). Human genetic studies have identified a 
number of potential analgesic targets, including neurotrophins, tran-
scription factors, and ion channels (2–4). The sodium channel NaV1.7 
expressed in sensory neurons is required for pain perception in mice 
and humans (5). NaV1.7 gain-of-function mutations result in ongoing 
pain in humans, while rare recessive loss-of-function mutants are 
pain free but otherwise normal apart from an inability to smell (6). 
NaV1.7 has been assumed to play an essential role in generating no-
ciceptive spiking in sensory neurons. However, it has other roles in 
pain pathways. In mice, deletion of NaV1.7 in sensory neurons leads to 
enhanced expression of opioid peptides and potentiated opioid re-
ceptor activity (7, 8). Much of the analgesia associated with loss of func-
tion of NaV1.7 in mice and humans can be reversed with the opioid 
antagonist naloxone, while NaV1.7 antagonist action is greatly poten-
tiated by low-dose opioids or enkephalinase blockers (9, 10). NaV1.7 
has also an unusual role as an integrator of synaptic input in the 
hypothalamus (11).
Anosmia associated with loss of NaV1.7 in olfactory neurons has been 
shown to result from lack of glutamate release (6). In somatosensory 
neurons, there is also a loss of substance P release from NaV1.7 null 
mutant sensory neurons, suggesting a regulatory role for NaV1.7 in 
the control of neurotransmitter release (12). To examine this mech-
anism, we generated an epitope-tagged NaV1.7 knock-in mouse that 
shows entirely normal pain behavior. We used this mouse first to iden-
tify NaV1.7 interacting proteins using immunoprecipitation and mass 
spectrometry (13) and then to examine the expression of NaV1.7 in 
the central terminals of sensory neurons using both immunocyto-
chemistry (ICC) and immuno–electron microscopy (immuno-EM).
RESULTS
NaV1.7 is expressed in primary afferent postsynaptic 
terminals in the dorsal horn
Immunohistochemical studies showed that the Tandem Affinity 
Purification (TAP)–tagged NaV1.7 is expressed in laminae I and II 
and part of lamina III in the spinal cord on the basis of coexpression 
with substance P, prostatic acid phosphatase (PAP), and vesicular 
glutamate transporter 1 (vGLUT1) (Fig. 1A). These data are consist-
ent with earlier studies that showed the coexpression of synaptophysin 
and NaV1.7 in lamina II of rat spinal cord (14). However, unexpectedly, 
immuno-EM showed that the TAP-tagged NaV1.7 is present not only 
in presynaptic sites of central terminals of peripheral sensory neurons 
but also in postsynaptic sites in dendrites in spinal cord neurons, as 
defined by ultrastructural criteria (Fig. 1B) (15, 16). Quantitation of 
immunoreactive particles showed an association of 60% of immuno-
reactive NaV1.7 with postsynaptic sites, where a third of immunoparticles 
were present on the membranes of dendritic shafts (Fig. 1C). Further, 
immunofluorescence confocal microscopy was consistent with the find-
ing that that the TAP-tagged NaV1.7 is expressed not only in the 
presynaptic terminals of sensory afferents but also in the postsynaptic 
terminals of interneurons in lamina II of the dorsal horn of the spinal 
cord (fig. S1).
Sensory neurons are the source of NaV1.7 in dorsal  
horn neurons
Does the dorsal horn neuron immunoreactive NaV1.7 originate from 
spinal cord mRNA transcripts? RNA sequencing studies of isolated 
neurons have identified some dorsal horn neurons that express NaV1.7 
mRNA (17). Using the sensitive technique of RNAscope, the expres-
sion of NaV1.7 mRNA in vivo in a subset of motor neurons is appar-
ent, but very few transcripts can be detected in dorsal horn cells (fig. S2) 
(18). We tested the origin of immunoreactive NaV1.7 in dorsal horn 
neurons using rhizotomy of L5 afferent spinal nerves followed by 
examination of TAP-tagged NaV1.7 by immuno-EM 4 weeks later 
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(Fig. 2). The result shows that the number of immunoparticles in 
the region of rhizotomized spinal cord is significantly lower compared 
to L5 sham controls (Fig. 2, A and B). The total number of immuno-
particles was reduced by about half in both presynaptic (axons) and 
postsynaptic terminals (dendrites) 4 weeks after rhizotomy (Fig. 2B). 
Compared to controls, no obvious changes were found in the relative 
distribution of immunoparticles in dorsal horn of rhizotomized mice, 
where approximately 40% residual particles were found in presyn-
aptic terminals and 60% in postsynaptic terminals in both sham con-
trol and rhizotomized mice (Fig. 2C). The residual immunoreactivity 
in rhizotomized dorsal horn neurons may represent degradation prod-
ucts or protein derived from ascending or descending primary af-
ferents entering the cord through the adjacent nontransected roots. 
The lifetime of NaV1.7 protein has been suggested to be in the region 
of weeks on the basis of adult deletion of the Scn9a gene in mice (19). 
Together, our evidence is consistent with the view that afferent nerves 
are the source of the immunoreactive NaV1.7 in the dorsal horn.
Electrophysiological properties of lamina II neurons are 
altered in primary afferent NaV1.7 knockout mice
To explore any possible functional relevance of channel transfer, we 
examined the electrophysiological properties of dorsal horn lamina II 
neurons from mice where NaV1.7 is deleted only in sensory neurons 
using Cre-recombinase driven by the advillin promoter. Lamina II 
neurons exhibit different firing properties following somatic current 
injections and can be classified according to their firing pattern 
as tonic, burst, single spike, or delayed firing (20). We investigated 
whether there were differences in the relative frequency of each 
type of neuron between wild-type (WT) and Dorsal Root Ganglion 
(DRG)–specific NaV1.7 knockout (KO) mice. All four types of firing 
pattern were observed in both WT and NaV1.7 KO animals, as shown 
in the representative traces of Fig. 3 (A and B). The prevalence of 
delay neurons was similar in WT (12 of 83) and NaV1.7 KO (6 of 50) 
mice, but the percentage of tonic neurons in NaV1.7 KO mice was 
less than half that in WT (NaV1.7 KO = 18% versus WT = 40%) 
mice. The reduction in the proportion of tonic neurons in NaV1.7 
KO mice was compensated by the prevalence of single spike (NaV1.7 
KO = 28% versus WT = 13%; Fig. 3, C and D) and, to a lesser extent, 
bursting cells (42% versus 33%; Fig. 2, C and D). The differences in 
neuronal populations in NaV1.7 KO compared to WT dorsal horn 
was statistically significant (P = 0.0018, 2 test). Our data suggest 
that dorsal horn neurons from NaV1.7 peripheral neuron KO mice 
have reduced excitability. This was confirmed by the observation 
that the maximum number of spikes recorded during a 4-s maximal 
current pulse (sufficient to evoke firing at maximal frequency without 
spike inactivation) was reduced (P = 0.0288, two-sample t test with 
Welch correction; Fig. 3E), with WT producing 51.7 ± 13.2 spikes 
(n = 83 neurons) and NaV1.7 KO generating 21.2 ± 3.8 spikes (n = 
50 neurons). We also demonstrated that there is a significant in-
crease in the AP threshold in NaV1.7 KO mice compared to WT 
neurons (P = 0.0483, two-sample t test with Welch correction; fig. S3D). 
As these events occur in mice where NaV1.7 is deleted only in sensory 
neurons, the deficits in dorsal horn neurons must result from a lack 
of translocated NaV1.7.
NaV1.7 blocker PF05089771 diminishes excitability in dorsal 
horn neurons
We extended this genetic analysis by recording from lamina II neurons 
in WT mice to determine their firing properties before and after 
Fig. 1. The distribution of NaV1.7 in the dorsal horn. (A) The distribution of TAP-
tagged NaV1.7 in the dorsal horn was detected using immunofluorescence with anti- 
FLAG antibody (left). The cross sections of spinal cord (lumbar 5) were costained with 
markers of superficial dorsal horn such as substance P (lamina I), PAP (lamina II), and 
vGLUT1 (lamina III onwards) antibodies (middle). The right panels show the 
merged left to middle panels. The results show that TAP-tagged NaV1.7 mainly ex-
presses in laminae I and II and in the part of lamina III. Scale bars, 100 m. (B) Sub-
cellular localization of TAP-tagged NaV1.7 in the dorsal horn of the spinal cord was 
identified with immuno-EM techniques. Electron micrographs showing immunola-
beling for FLAG in the dorsal horn of the spinal cord were detected using the 
pre-embedding immunoperoxidase (top) and immunogold techniques (bottom). 
Using the pre-embedding immunoperoxidase method, peroxidase reaction end- 
product for FLAG in the TAP-tagged NaV1.7 mice was detected filling dendrites 
(Den) and dendritic spines of spinal cord neurons, as well as at presynaptic sites 
filling axon terminals (at). In the WT mice (top right), no peroxidase reaction 
end-product for FLAG was detected in the spinal cord. Using the pre-embedding 
immunogold method, immunoparticles for FLAG present in the TAP-tagged 
NaV1.7 were mainly detected at intracellular sites (arrowheads in red), as well as 
along the plasma membrane (arrowheads in green) in dendritic shafts (Den) of spi-
nal cord neurons. In addition, immunoparticles for FLAG were observed along the 
extrasynaptic plasma membrane (arrowheads in blue) of axon terminals (at). In the 
WT mice (bottom right), a very low density of immunoparticles for FLAG, similar to 
background levels, was observed attached to mitochondria in the spinal cord. 
Scale bars, 500 nm. HRP, horseradish peroxidase. (C) The number of immunoparti-
cles in the superficial dorsal horn of TAP-tagged NaV1.7 mice was counted. Of 1253 
immunoparticles, 768 particles were located at postsynaptic sites (61%) and 485 
particles were located at presynaptic sites (39%). Along the 768 postsynaptic parti-
cles, 501 particles were located at intracellular sites (65%), and 267 particles were 
located along the plasma membrane (35%). Along the 485 presynaptic particles, 
204 particles were located at intracellular sites (42%), and 281 particles were located 
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application of PF05089771 (henceforth PF771), a selective blocker of 
NaV1.7 channels (21). Application of the blocker changed the firing 
pattern in a minority of cells (6 of 24; Fig. 4A, top). Three burst fir-
ing neurons became single spiking neurons, two tonic firing neurons 
became burst firing, and one tonic firing neuron became single spik-
ing in the presence of PF771. In addition, in 10 of 24 neurons, the 
rheobase significantly increased following application of PF771 
(median, 32.5 to 62.5 pA; P = 0.00586, paired Wilcoxon signed rank 
test; Fig. 4B). Consistently, in those cells in which PF771 increased 
rheobase, the median of the maximum number of spikes decreased 
from 26 to 6 spikes (P = 0.0438, paired Wilcoxon signed rank test). 
In contrast, in 14 of 24 cells in which rheobase was not significantly 
affected (median, 25 to 22.5 pA; P = 0.1; fig. S3B), the median number 
of spikes did not change significantly (median, 33.5 and 36.5; P = 
0.358, paired Wilcoxon signed rank test; fig. S3C). In the neurons in 
which rheobase was increased, the voltage threshold was also differ-
entially affected: In the groups of cells responding to PF771, the median 
voltage threshold was −37.6 mV in control and increased to −34 mV 
(P = 0.00805, paired Wilcoxon signed rank test), while it did not 
change for the nonresponding cells (median, −37.4 to −38 mV; P = 
0.286; fig. S4).
Note that the block by PF771 at this concentration is only effec-
tive after channels have been inactivated by a prolonged depolarization 
(cells that exhibited a change in input resistance of 10% or more 
following this depolarization were discarded from further analysis; see 
Methods). Because any NaV1.7 channels located on primary afferents 
would not have been inactivated and would be insensitive to PF771, 
the effects observed are specific to postsynaptic NaV1.7 on dorsal horn 
neurons. These data confirm that functional NaV1.7 channels are 
expressed on the postsynaptic membrane of a subset of lamina II 
neurons, and their activation contributes to neuronal excitability.
To confirm the specificity of the action of PF771, we repeated the 
same experiments with NaV1.7 KO mice, measuring the electro-
physiological properties of n = 16 lamina II neurons. In NaV1.7 KO 
mice, there was no significant change in rheobase (median, 57.5 to 
50 pA; P = 0.504), maximum number of spikes (median, 3.5 to 2.5; 
P = 0.181), or threshold (−36.7 to −37.1 mV; P = 0.514) in the pres-
ence of PF771 (Fig. 4, E to G). This indicates that KO of NaV1.7 in 
presynaptic afferent sensory neurons results in a functional deficit 
postsynaptically in the superficial dorsal horn.
DISCUSSION
Our functional studies demonstrate that the excitability, threshold, 
and firing pattern of a subset of dorsal horn neurons can be ascribed 
to the presence of primary afferent sensory neuron–derived NaV1.7. 
Fig. 2. TAP-tagged NaV1.7 is down-regulated in the spinal cord after dorsal rhizotomy. Four weeks after dorsal rhizotomy on the right L5, the spinal cords of TAP-
tagged NaV1.7 mice were extracted, and immuno-EM was performed with anti-FLAG antibody and pre-embedding immunogold techniques on the sections adjacent to 
L5. (A) Representative immuno-EM images from sham control (Sham Ctrl, left) and rhizotomy (right). Immunoparticles for FLAG were detected at intracellular sites (arrow-
heads in red), plasma membrane (arrowheads in green) in dendritic shafts (Den) of spinal cord neurons, and along the extrasynaptic plasma membrane (arrowheads in 
blue) of axon terminals (at). Scale bars, 200 nm. (B) The total numbers of immunoparticles from sham control samples (in gray) and rhizotomy (in red) indicate that the 
expression of TAP-tagged NaV1.7 is down-regulated by about 50% in both presynaptic and postsynaptic terminals after 4 weeks of rhizotomy. (C) Distribution (%) of im-
munoparticles in both presynaptic and postsynaptic terminals in the rhizotomy model. The numbers of immunoparticles were counted from both presynaptic and 
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These findings have significance for analgesic drug development and 
help to explain the failure of peripherally restricted NaV1.7 antagonists 
to be effective analgesics (9). NaV1.7 loss, apart from effects on sen-
sory neuron excitability, increases endogenous opioid drive, inhib-
its neurotransmitter release, and, as we have shown here, diminishes 
dorsal horn excitability. The relative importance of these regulatory 
steps in NaV1.7 loss-of-function analgesia is uncertain. Nonetheless, 
our findings demonstrate intercellular transport of NaV1.7, a func-
tional role for the channel in recipient cells, and a pattern of NaV1.7 
expression that differs from that predicted by transcriptomic stud-
ies. NaV1.7 antagonists have yet to produce as profound analgesia 
as loss of the encoding gene itself, probably because complete channel 
block seems to be required to induce opioid peptide expression (7). 
These results support the view that targeted ablation of Scn9a in 
sensory neurons may be a more productive approach to analgesia 
than the development of small-molecule antagonists of NaV1.7.
What is the mechanism of trans-neuronal transfer of NaV1.7? Ev-
idence for protein transfer between cells has been obtained in the 
immune system (trogocytosis) (22), with transcription factors (23), 
through trans-synaptic transfer and via exosome release (24). The trans- 
neuronal transfer of synuclein has been linked to neurodegenerative 
disease (25). Recent studies also demonstrate trans-synaptic trans-
fer of RNA via the activity-dependent immediate early retrotrans-
poson capsid–like ARC protein that is linked to synaptic plasticity, 
memory formation, and neuropsychiatric disease (26). It seems that 
circuitry within the brain involves not only electrical signaling but also 
activity-dependent transfer of RNA and proteins. This is the first 
example of peripherally encoded proteins exerting effects on central 
nervous system function. However, the mechanism of NaV1.7 trans-
fer remains to be established.
METHODS
Animals
Both female and male mice aged 4 to 8 weeks were kept on a 12-hour 
light/dark cycle and provided with food and water ad libitum. Con-
ditional NaV1.7 KO mice were generated by crossing floxed (SCN9A) 
NaV1.7 mice with Advillin-Cre mice (27). NaV1.7TAP knock-in mice 
were generated as described previously (13). All experiments were 
performed with approval from the United Kingdom Home Office 
according to guidelines set by personal and project licenses, as well as 
guidelines of the Committee for Research and Ethical Issues of IASP 
(International Association for the Study of Pain).
Immunocytochemical studies
The perfusion and staining were performed as previously described (28). 
Briefly, after deep anesthesia with pentobarbitone sodium solution 
(80 mg/kg; Pentoject, 57-33-0, Animal-care) by intraperitoneal in-
jection (e.g., 20 l/25 g of mouse), animals were transcardially per-
fused with 10 ml of heparinized saline [0.9% (w/v) NaCl; heparin 
(10 U/ml), Wockhardt UK Ltd.], followed by 25 ml of freshly pre-
pared 4% (w/v) paraformaldehyde in 0.1 M phosphate buffer (PB; 
pH 7.4) (containing 15% saturated picric acid and 0.1% glutaraldehyde 
for immuno-EM). After perfusion, the spinal cords were removed, 
postfixed in the same fixative solution at 4°C overnight, and then 
cryoprotected in 30% (w/v) sucrose containing 0.02% sodium azide in 
0.1 M PB overnight. Subsequently, the sections were cut at a thick-
ness of 60 m on a vibratome (VT1000S, Leica), then incubated in 
50% ethanol for 30 min, blocked in a blocking buffer [1× phosphate- 
buffered saline (PBS) containing 0.3% Triton X-100 containing 5% 
donkey serum] at room temperature for 1 hour, and then incubated 
in primary antibodies diluted in the blocking buffer at 4°C overnight. 
Fig. 3. Electrophysiological properties of lamina II neurons are altered in sensory neuron–specific NaV1.7 KO mice. Representative traces of the four main firing 
patterns of lamina II neurons recorded from ex vivo spinal cord slices from (A) WT and (B) NaV1.7 KO mice. Current injections are not shown for clarity. Current injections 
for recordings shown were as follows: WT tonic = 80 pA, WT single = 200 pA, WT delay = 200 pA, WT burst = 60 pA, KO tonic = 30 pA, KO single = 100 pA, KO delay = 70 pA, 
and KO burst = 50 pA. Percentage of each neuronal subpopulation in lamina II from (C) WT (n = 83 neurons) and (D) NaV1.7 KO (n = 50 neurons) mice. (E) Maximum num-
ber of spikes elicited by current injection for each neuron compared between WT and NaV1.7 KO mice. The difference is statistically significant (*P = 0.02875, two-sample 
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After three washes in PBS, the sections were incubated in the secondary 
antibodies at room temperature in the dark for 2 hours. Later, the 
sections were rinsed three times in PBS and then placed onto SuperFrost 
Plus (Ref J1800AMNZ, Thermo Fisher Scientific) slides, mounted 
in an Antifade Mounting Medium (H-1000, Vector Laboratories), 
covered with coverslip, and sealed with nail varnish. Last, the sections 
were scanned with a Zeiss LSM 710 204 confocal microscope. The 
primary antibodies are anti-FLAG (1:100; F1804, Sigma), anti–substance 
P (1:200; OBT06435, Oxford Biotec), anti-PAP (1:1000; AAF23171, 
Aves Lab Inc.), anti-vGLUT1 (1:5000; AB5905, Chemicon), anti- 
Homer (1:1000; Frontier Institute, AB_2631104), and anti-vGLUT2 
(1:5000; ab2251, Millipore). The secondary antibodies are donkey 
anti-mouse A488 (1:1000; 715-545-150, Jackson ImmunoResearch), 
donkey anti-chicken (1:1000; 703-025-155, Jackson ImmunoResearch), 
donkey anti-rat A647 (1:1000; 712-605-153, Jackson ImmunoResearch), 
donkey anti–guinea pig Pacific Blue (1:1000; 706-475-148, Jackson 
ImmunoResearch), and donkey anti-goat Rhodamine Red (1:1000; 
705-025-003, Jackson ImmunoResearch).
Immunohistochemistry for electron microscopy
Immunohistochemical reactions for electron microscopy were carried 
out using the pre-embedding immunoperoxidase and immunogold 
methods described previously (15). Briefly, 10-week-old TAP-tagged 
NaV1.7 mice (n = 3) and WT littermate control mice (n = 3) were used 
for immuno-EM. After being deeply anesthetized, the cross sections 
from lumbar 4 to 5 of spinal cords were prepared as above (immuno-
fluorescence). Subsequently, the free-floating sections were blocked 
and incubated with a monoclonal anti-FLAG (3.5 g/ml; F1804, 
Sigma) antibody in blocking buffer [tris-buffered saline (TBS) con-
taining 1% (v/v) normal goat serum (NGS)]. They were incubated 
in biotinylated goat anti-mouse immunoglobulin G (IgG; Vector 
Laboratories) or in goat anti-mouse IgG coupled to 1.4 nm of gold 
(Nanoprobes Inc., Stony Brook, NY, USA) diluted in TBS containing 
1% NGS. For immunoperoxidase, the sections were then transferred to 
an avidin- biotinylated peroxidase mixture (ABC kit, Vector Laboratories) 
diluted as 1:100 for 2 hours at room temperature. Peroxidase enzyme 
activity was revealed by using a 3,3′-diaminobenzidine tetrahydrochloride 
solution (0.05% in TB, pH 7.4), to which 0.01% H2O2 was added. For 
immunogold, the sections were postfixed in 1% (v/v) glutaraldehyde 
and washed in double-distilled water, followed by silver enhance-
ment of the gold particles with an HQ Silver kit (Nanoprobes Inc.). 
All sections were then treated with osmium tetraoxide (1% in 0.1 M 
PB), block-stained with uranyl acetate, dehydrated in graded series 
of ethanol, and flat- embedded on glass slides in Durcupan (Fluka) 
resin. Regions of interest were cut at 70 to 90 nm on an ultramicrotome 
(Reichert Ultracut E, Leica, Austria) and collected on single-slot 
Fig. 4. Effect of specific NaV1.7 blocker PF771 on lamina II neurons from WT and NaV1.7 KO mice. Two populations of WT neurons were identified: neurons that displayed 
an increase in rheobase and neurons that showed little or no change in rheobase in the presence of PF771 (see fig. S4). (A) Representative WT burst firing neuron displaying 
an effect of PF771 on firing. (B) Representative NaV1.7 KO burst firing neuron displaying no effect of PF771 on firing. Current injections for traces were as follows: WT burst = 30 pA 
and NaV1.7 KO burst = 50 pA. Current injections were identical before and after drug. (B) WT neurons were split on the basis of rheobase change in the presence of PF771. 
Paired WT neurons displayed an increase in rheobase with PF771 (hatched bar) versus control (open bar; *P = 0.00586, paired Wilcoxon signed rank test) (C) Maximum number 
of spikes (at the same current injection before and after drug) was significantly reduced with PF771 versus control (#P = 0.04383, paired Wilcoxon signed rank test) in WT 
neurons showing an increase in rheobase only. (D) Threshold was significantly increased with PF771 versus control (**P = 0.00178, paired Wilcoxon signed rank test) in WT 
neurons showing an increase in rheobase only. There were no major population differences in terms of response to PF771 identified in NaV1.7 KO mice dorsal horn neurons. 
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pioloform-coated copper grids. Staining was performed on drops 
of 1% aqueous uranyl acetate, followed by Reynolds’s lead citrate. 
Ultrastructural analyses were performed in a JEOL JEM-1010 
electron microscope.
Dorsal rhizotomy and immuno-EM
The procedure of dorsal rhizotomy in the region of lumbar dorsal root 
ganglion 5 (L5) was performed as described (29). Briefly, 8-week-old 
TAP-tagged NaV1.7 mice were anesthetized with 2 to 3% isoflurane 
in oxygen (0.5 liter/min), and then a laminectomy on L5 of spinal 
cord was followed by unilateral transection of the right L5 dorsal roots 
(Rhizotomy). For the sham controls (Sham Ctrl), the same procedures 
were performed as rhizotomy except transection. Four weeks after 
the surgery, the mice were perfused with 4% paraformaldehyde in PBS 
containing 0.1% glutaraldehyde (Sigma, G5882). After perfusion, the 
spinal cords were removed and postfixed in the same fix ative at 4°C 
overnight. Then, the tissues were placed in 30% sucrose in 1× PBS 
at 4°C overnight. The spinal cords were sectioned, and immuno-EM 
was performed as described in the main text. For counting the number 
of immunoparticles in laminae I, II, and III of right L5 spinal cords, 
50 electronic microscope images were randomly taken from each sample. 
The surface area of each image is 15 m2. Therefore, the total number 
of each sample will represent immunoparticles in the surface of 750 m2.
Spinal cord preparation
Spinal cord preparations were obtained from male or female mice, 
between 30 and 60 days old, from either WT C57Bl/6 or conditional 
NaV1.7 KO (NaV1.7 KO). Animals were anesthetized via intraperi-
toneal injection of a ketamine/xylazine mix (80 and 10 mg/kg, re-
spectively) and decapitated. The spinal cord was dissected in ice-cold 
artificial cerebrospinal fluid (aCSF) of the following composition: 
113 mM NaCl, 3 mM KCl, 25 mM NaHCO3, 1 mM NaH2PO4, 2 mM 
CaCl2, 2 mM MgCl2, and 11 mM d-glucose, and the same solution 
was used for subsequent electrophysiological recordings. Once dis-
sected free from the vertebral column, the spinal cord was carefully 
cleaned from connective tissues, and dorsal roots were cut at approx-
imately 2 mm in length. The spinal cord was then glued to an agar 
block and glued to the slicing chamber of an HM 650V vibratome 
(Microm, Thermo Fisher Scientific, UK). The solution used for slicing 
contained 130 mM k-gluconate, 15 mM KCl, 0.05 mM EGTA, 20 mM 
Hepes, 25 mM d-glucose, 3 mM kynurenic acid, 2 mM Na-pyruvate, 
3 mM myo-inositol, 1 mM Na-l-ascorbate, and pH 7.4 with NaOH 
(30). Slices were incubated for 40 min at 35° and then allowed to 
equilibrate at room temperature for a further 30 min before starting 
the recordings.
Electrophysiology
Current and voltage clamp recordings were performed using either a 
Molecular Devices Multiclamp 700B amplifier (Scientifica, UK) or an 
ELC-03X amplifier (NPI electronic, Germany). Signals were filtered 
at 5 KHz, acquired at 50 KHz using a Molecular Devices 1440A A/D 
converter (Scientifica, UK), and recorded using Clampex 10 software 
(Molecular Devices, Scientifica, UK). Electrodes were pulled with a 
Flaming-Brown puller (P1000, Sutter Instruments, USA) from bo-
rosilicate thick glass (GC150F, Harvard Apparatus, UK). The resist-
ance of the electrodes, following fire polishing of the tip, ranged 
between 3 and 5 megohms. Bridge balance was applied to all record-
ings. Intracellular solution contained 125 mM k-gluconate, 6 mM KCl, 
10 mM Hepes, 0.1 mM EGTA, 2 mM Mg–adenosine triphosphate 
(ATP), pH 7.3 with KOH, and osmolarity of 290 to 310 mOsm. Cells 
were included for further analysis if their input resistance throughout 
the duration of the experiment was stable (within 10% of its initial value) 
and if their spikes (evoked by a current step) peaked beyond 5 mV.
Cells were targeted in the inner and outer lamina II and visualized 
using an Eclipse E600FN Nikon microscope (Nikon, Japan) equipped 
with infrared differential interference contrast connected to a digi-
tal camera (Nikon, DS-Qi1Mc). In most experiments, a dorsal root 
was stimulated via a section electrode connected to an isolated cur-
rent stimulator (DS3, Digitimer, UK). The stimulation intensity was 
fixed at 5× threshold for evoking the low threshold response in the 
recorded cell (typically 50 to 100 A). Cells were held in current clamp 
mode, and their resistance and capacitance were measured from the 
voltage response to a brief (20 ms) current step (10 to 20 pA). Rheobase 
was defined as the minimum current necessary to elicit a spike. Cells 
were classified into tonic (firing continuously throughout a current 
step), single spike (firing only once at the beginning of the current 
step), delayed (firing during the course of the current step), and 
bursting (firing more than one spike at the start of the current step).
PF771 was bath-applied through perfusion at a concentration of 
100 nM. It has been shown that at our chosen concentration of 
PF771 has no blocking effect on NaV1.7 unless the channels are in-
activated (21). In our experimental conditions, the response to cur-
rent injection was never affected by the presence of the blocker. The 
drug effects were observed only after NaV1.7 channels were inacti-
vated by holding the cell at depolarized potential (0 mV) for 30 s. 
Cells that exhibited a change in input resistance of 10% or more fol-
lowing this depolarization were discarded from further analysis. Cells 
were defined as “responsive” to the channel blocker if their rheobase 
increased by at least 10% in the presence of PF771. All drugs were 
obtained from Sigma-Aldrich unless stated otherwise.
Data analysis and statistics
For electrophysiological data, the spike kinetic parameters (spike width, 
height, threshold, and maximum rate of rise and descent) were mea-
sured using custom-written software [Bayesian Quantal Analysis suite, 
freely downloadable at http://sourceforge.net/projects/pyclamp/ (31)]. 
All other statistical and data analyses were performed with Origin 
Lab 2018, GraphPad Prism 7.0, Microsoft Excel, or Zeiss Zen Blue 
microscopy software. Values are expressed as the means ± SEM. The 
statistical significance of the data was analyzed using Student’s t test. 
Significant differences between two groups were examined statisti-
cally as indicated (*P < 0.05, **P < 0.01).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/8/eaax4568/DC1
Supplementary Materials and Methods
Fig. S1. The distribution and colocalization of NaV1.7 in the dorsal horn.
Fig. S2. Levels and distribution of Scn9a transcript in mouse spinal cord.
Fig. S3. Intrinsic properties of WT and NaV1.7 KO superficial dorsal horn neurons.
Fig. S4. “PF771-unresponsive” WT superficial dorsal horn neurons.
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